Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody.
Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody.
复制标题
血清中期因子作为甲状腺球蛋白抗体阳性分化型甲状腺癌患者转移预测的替代生物标志物
DOI：
10.1038/srep43516
复制
发表时间：
2017-02-27
影响因子：
4.6
通讯作者：
Zhang C
中科院分区：
文献类型：
--
作者：
Jia Q;Meng Z;Xu K;He X;Tan J;Zhang G;Li X;Liu N;Hu T;Zhou P;Wang S;Upadhyaya A;Liu X;Wang H;Zhang C
血清甲状腺球蛋白（Tg）是分化型甲状腺癌（DTC）患者术后主要的肿瘤生物标志物。然而，甲状腺球蛋白抗体（TgAb）的存在会干扰Tg水平并使测试无效。本研究旨在探讨中期因子（midkine，MK）作为肿瘤生物标志物对初次131 I治疗前TgAb阳性的DTC患者的预测价值。MK水平测定酶联免疫吸附试验在151招募DTC患者行使严格的纳入和排除标准。TgAb阳性的有转移的DTC患者28例，无转移的DTC患者123例。通过受试者工作特征曲线（ROC）评估131 I消融前MK预测转移的价值。TgAb阳性的DTC患者MK水平显著高于无转移的DTC患者。ROC曲线显示MK具有良好的预测性，曲线下面积为0.856（P < 0.001），在550 pg/ml的最佳临界值下，诊断准确率为83%。总之，我们表明MK可以潜在地用作预测DTC转移的替代生物标志物，当Tg由于TgAb阳性而不适合时。
Serum thyroglobulin (Tg) is the main post-operative tumor biomarker for patients with differentiated thyroid cancer (DTC). However, the presence of thyroglobulin antibodies (TgAb) can interfere with Tg level and invalidate the test. In this study, we aimed to investigate the predicative value of midkine (MK) as a cancer biomarker for DTC patients with positive TgAb before the first131I therapy. MK levels were measured by enzyme-linked immunosorbent assay in 151 recruited DTC patients after exercising strict inclusion and exclusion criteria. There were 28 TgAb positive DTC patients with metastases and 123 DTC patients without metastases. The value of pre-131I-ablative MK to predict metastasis was assessed by receiver operating characteristic (ROC) curves in these two groups of patients. MK levels in the TgAb positive DTC patients were significantly higher than the DTC patients without metastases. ROC showed good predictability of MK, with an area under the curve of 0.856 (P < 0.001), and a diagnostic accuracy of 83% at the optimal cut-off value of 550 pg/ml. In conclusion, we show that MK can potentially be used as a surrogate biomarker for predicting DTC metastases when Tg is not suitable due to TgAb positivity.